Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05271318
Title Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)
Acronym PROTA
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors TILT Biotherapeutics Ltd.
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.